European Psychiatry - Volume 41 - April 2017

757 / 916

25th European Congress of Psychiatry / European Psychiatry 41S (2017) S710–S771 S753
incoherent language appeared for the first time at the age of 17.
High doses of two consecutive anti-psychotics were tried without
remission and finally clozapine was initiatedwith clinical improve-
ment.
Discussion In clinical practice, a subgroup of psychotic patients
experience, significant ongoing positive symptoms despite of using
first line anti-psychotic medication.
Conclusion Most recent research; suggest that clozapine may
have an important role in the early treatment of first-episode
patients, even becoming a first line option to consider.
Keywords Clozapine; First episode psychosis
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1073
Long acting injectable aripiprazole:
An observational study
N. Garcia ∗, J. Brotons , R. Genoves , J. Martinez-Raga , C. Saez ,
R. Calabuig
Doctor Peset University Hospital, Mental Health Service, Valencia,
Spain
∗ Corresponding author.
Introduction Several trials have shown the efficacy of long acting
injectable (LAI) second-generation anti-psychotics compared with
other anti-psychotics. LAI aripiprazole is a novel therapeutic tool
in the management of patients with schizophrenia.
Aims The present study aimed to evaluate the clinical outcomes
of patients who initiated treatment with LAI aripiprazole, by com-
paring their clinical outcomes prior and after initiating treatment
with LAI aripiprazole.
Methods This observational, retrospective, mirror study assessed
a series of socio-demographic and clinical variables during the
12months prior to commencing LAI aripiprazole, while on another
anti-psychotic medication, and the first 12months of LAI aripipra-
zole. The sample included a series of consecutive patients receiving
LAI aripiprazole at the Doctor Peset university hospital health area,
in Valencia (Spain). The variables analyzed in the study included:
emergency room visits, number and average length of hospitaliza-
tions, relapse, rate of abandonment of treatment and number of
anti-psychotics needed as maintenance treatment.
Results The preliminary analysis showed a reduction in the rate
of emergency room visits and the number of relapse and total
hospitalizations while on LAI aripiprazole; however, there is no
a reduction of the average length of hospitalizations. A reduction
in the number of anti-psychotics as maintenance treatment was
not appreciated, however, there was an improvement in treatment
adherence.
Conclusions The preliminary results showed that LAI aripipra-
zole is an useful option that could suppose a benefit concerning
treatment adherence, a decreased in number of relapses and hos-
pitalizations and use of health resources.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1074
A pharmacologic option to reduce
hospital admissions and relapses of
patients with severe mental illness
N. Gomez-Coronado ∗, P. Blanco , I. Martinez
Hospital Virgen del Rocio, Psychiatry, Sevilla, Spain
∗ Corresponding author.
Introduction Some diseases relapses involve functional impair-
ment that sometimes takes years to recover. We present our
experience using long-acting aripiprazole as maintenance therapy
in patients diagnosed with psychotic episode, acute mania (bipo-
lar disorder) or personality disorder, who were previously treated
with another anti-psychotic.
Aims Analyze what treatment were they taking before aripipra-
zole depot. Determine the number of hospital admissions and
relapses before and after long-acting aripiprazole treatment.
Methods Descriptive analysis based on a sample of 37 patients,
aged 18–65 years, treated during one year with anti-psychotics at
two community mental health units.
Results Reduction of hospitalization average: 0.59/year with
non-long-acting-aripiprazol anti-psychotic, 0.18/year with long-
acting aripiprazol (66.6%).
Conclusion Long-acting aripiprazole appears to reduce the
number of hospitalizations and relapses compared to other anti-
psychotics. However, the sample size is small and more studies are
needed.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1075
Tobacco and anti-psychotics side
effects
I. González González , A. Hernández Dorta∗
Hospital Universitario de Canarias, Psiquiatría, La Laguna, Spain
∗ Corresponding author.
Introduction It’s known that, patients with schizophrenia smoke
more tobacco than general population, and that tobacco is a potent
inducer of cythocrome P450 isoenzyme 1A2 (CYP 1A2). In addition,
clozapine and quetiapine, drugs frequently used in the treatment
of schizophrenia, are CYP1A2 substrates. So, tobacco smoking may
reduce blood levels of clozapine and quetiapine.
Objective To revisit the influence of changes in tobacco consump-
tion in clozapine and quetiapine side effects.
Methods Case report.
Results A 48-year-old male diagnosed of schizophrenia follow-
ing DSM IV-TR criteria. He required five hospital admissions from
2008 to 2013 because of psychotic episodes. Since 2013, he was
asymptomathic receiving clozapine, 600mg/day, and quetiapine,
1200mg/day. Recently, he came to the emergency service due to
sudden extreme sedation, thinking impairment, sialorrhea, and
walking disability. The patient denied treatment abuse and his fam-
ily confirmed this statement. When asked about toxics he referred
progressive tobacco reduction in the last 3months (from 60 to 20
cigarettes/day). Bearing in mind the relationship between clozap-
ine and quetiapine metabolism and tobacco, treatment was slowly
reduced until the doses of clozapine 500mg/day and quetiapine
400mg/day. One week after admission, side effects disappeared,
psychotic symptoms were not detected, and the patient was dis-
charged.
Conclusions Inquiring about changes in tobacco consumption
may be useful when anti-psychotics side effects appear suddenly
without an alternative explanation.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1076
Sex and age factors in neuroleptic
malignant syndrome diagnosis
frequency
R. Gurrera
VA Boston Healthcare System, Mental Health/Psychiatry, Brockton,
USA